According to a federal appeals court ruling, patients with terminal illnesses do not have a constitutional right to use medicines that have not yet won regulatory approval. The 8-to-2 decision by the Court of Appeals for the District of Columbia Circuit came after a closely watched and emotional case that saw desperate patients willing to try unproven, even risky, therapies come against those arguing that drugs should be proved safe and effective before they are made available.
The decision preserves the current regulatory system. If it had gone the other way “it would have undermined the entire drug approval process,” opines William B. Schultz, a former deputy commissioner of the Food and Drug Administration.
The case was filed against the Food and Drug Administration in 2003 by the Abigail Alliance for Better Access to Developmental Drugs, a group founded by a man whose daughter Abigail died from cancer after a long battle to receive treatment with experimental drugs that were eventually approved.
The group, joined by the Washington Legal Foundation, argued that forcing patients to wait years for a drug to go through the process of clinical trials deprived dying patients of their right to self-defense and violated the Fifth Amendment clause stating that people cannot be deprived of life, liberty or property without due process of law.
A district court ruled against the Abigail Alliance. Though an appeals court panel reversed the decision, the full appeals court yesterday upheld the original district court decision.
Judge Thomas B. Griffith, writing for the majority, said a right to experimental drugs was not deeply rooted in the nation’s history and tradition. Judge Griffith said the right of self-defense “cannot justify creating a constitutional right to assume any level of risk without regard to the scientific and medical judgment expressed through the clinical testing process.”
Frank Burroughs, the founder of the Abigail Alliance, said his group was “dumbfounded that most of the justices tragically missed the merits of the case.” Mr. Burroughs vowed to appeal to the Supreme Court.
The agency sometimes does lower the bar for approval of medicines for life-threatening diseases. And the companies developing such drugs can make them available before approval under some circumstances.But Mr. Burroughs said such programs were inadequate. His organization advocates that drugs be made available to terminally ill patients as early as the conclusion of the first of three phases of clinical trials.
Yet, some drug companies, doctors and other patient groups oppose that idea. Mr. Schultz, for instance, filed his brief supporting the current system on behalf of the National Organization for Rare Disorders, a patient advocacy group.
He and others say that if drugs were made available after only preliminary testing, drug companies would have little incentive to conduct full clinical trials to determine if a drug really works. That would allow companies to “profit from offering empty hope,” says Robert Erwin of the Marti Nelson Cancer Foundation, a patient advocacy group.